ABMC Phone: 800-227-1243

ABMC Reports First Quarter 2011 Results

KINDERHOOK, N.Y. - May 13, 2011 - American Bio Medica Corporation (Pink Sheets: ABMC) today announced financial results for the three months ended March 31, 2011.

Net sales for the first quarter of 2011 were $2,047,000, a decrease of $379,000, or 15.6%, when compared to net sales of $2,426,000 in the first quarter of 2010. Operating loss for the first quarter was $374,000, compared to an operating loss of $219,000 reported in the first quarter of 2010. Net loss for the first quarter of 2011 was $425,000, or $0.02 per share, compared to a net loss of $276,000, or $0.01 per share for the first quarter of 2010.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2010, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

(financial tables follow)

Statements of Operations
(in thousands, except loss per share)
For the three For the three
months ended months ended
March 31, 2011 March 31, 2010
Net sales $ 2,047 $ 2,426
Cost of goods sold 1,285 1,475
Gross profit 762 951
Operating expenses:
Research and development 52 102
Selling and marketing 457 487
General and administrative 627 581
Total operating expenses 1,136 1,170
Operating loss (374 ) (219 )
Other expense (51 ) (54 )
Net loss before tax (425 ) (273 )
Income tax expense (3 )
Net loss $ (425 ) $ (276 )
Basic & diluted loss per common share $ (0.02 ) $ (0.01 )
Basic & diluted weighted average shares outstanding 21,745 21,745

(Balance Sheets follow)
American Bio Medica Corporation
Balance Sheets
(in thousands)
March 31, December 31,
Current Assets
Cash and cash equivalents $ 83 $ 37
Accounts receivable, net of allowance for doubtful accounts
of $66,000 at March 31, 2011 and $76,000 at December 31, 2010 889 743
Inventory, net of allowance for slow moving and obsolete
inventory of $207,000 at March 31, 2011 and $213,000 at December 31, 2010
3,389 3,604
Prepaid expenses and other current assets 145 121
Total current assets 4,506 4,505
Property, plant and equipment, net 1,342 1,409
Debt issuance costs, net 62 72
Other assets 29 29
Total assets $ 5,939 $ 6,015
Current liabilities
Accounts payable 698 432
Accrued expenses and other current liabilities 219 287
Wages payable 276 252
Line of credit 652 493
Current portion of long-term debt and unearned grant 126 140
Total current liabilities 1,971 1,604
Other liabilities 141 140
Long-term debt 1,449 1,480
Related party note 124 124
Unearned grant 10 10
Total liabilities 3,695 3,358
Stockholders’ Equity:
Common stock 217 217
Additional paid-in capital 19,341 19,328
Accumulated deficit (17,314 ) (16,888 )
Total stockholders’ equity 2,244 2,657
Total liabilities and stockholders’ equity $ 5,939 $ 6,015

American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer